The UWCCC/WON Molecular Tumor Board (MTB) & Registration Protocol Mark E. Burkard MD PhD WON fall meeting October 24, 2015.

Slides:



Advertisements
Similar presentations
Joint Portal USER CONFERENCE & SYMPOSIUM 2013 MASTERING HEALTHCARE STRATEGIES AUSTINTEXAS.
Advertisements

Cancer Registry Follow-up How we do it
Biologics for Children with Rheumatic Diseases An Introduction.
1 The HIPAA Privacy Rule and Research This presentation will probably involve audience discussion, which will create action items. Use PowerPoint to keep.
Customized Laboratory Support Roxann Neumann, RN, BSN, CCRP ACCRU Biospecimen Resource Manager.
EDRN’s Validation Study Information Management System Developed for EDRN by the DMCC Cancer Biomarkers Group Division of Cancer Prevention Jet Propulsion.
Introduction & Objectives
Longhorn Council Units can enter ranks, merit badges, and awards online.
TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER Libraries of The Health Sciences MSIII’s Internal Medicine Clerkship Point of Care Evidence Based Medicine.
Search Your Doctor By Specialty or Location or by Name.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Use Case 7 IHE Profiles & Actors Care Theme: Leveraging Healthcare Registries in Care Delivery Use Case: Optimizing Cancer Care Coordination Leveraging.
S H Subramony M.D. Professor of Neurology McKnight Brain Institute and University of Florida College of Medicine Gainesville, FL.
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
POWERSCHOOL AND COURSE SELECTIONS THE PARENT EXPERIENCE Making Online Course Selections for the Next School Year.
Human Research Protection Programs 1a: How to Navigate Human Subject Protection Regulations Sponsored by the American Society for Investigative Pathology.
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
Medical Expert Systems Eddie Lai. History  1950s – scientists tried to use computers for “probabilistic reasoning and statistical pattern recognition”

Long Term Follow Up of Subjects in Gene Transfer Clinical Trials Philippe Bishop, MD FDA/CBER Division of Clinical Trial Design and Analysis Oncology Branch.
1 Jack London, PhD Research Professor, Cancer Biology Thomas Jefferson University Informatics Shared Resource Director Sidney Kimmel Cancer Center at Jefferson.
CASEFINDING Debra W. Christie, MBA, RHIA, CTR, CCRP Director, Cancer Research & Data Center University of Mississippi Medical Center.
Patterns of Care in Medical Oncology Adjuvant Systemic Therapy for Colon Cancer.
H I P A A T R A I N I N G Self Directed Module 7 Research Disclosures For Data Custodians START Click to begin…
Quest Diagnostics Clinical Trials
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
Tissue Banking Operations and Infrastructure Mid-Atlantic Pathologists Assistants and Pathologists Assistants of New England June 5 th 2009 Beacon Hotel,
NIA LOAD Genetics Initiative Progress Report 2007: NCRAD and LOAD Update Kelley Faber, MS, CCRC National Cell Repository for Alzheimer’s Disease.
© 2013 Cisco and/or its affiliates. All rights reserved. Cisco Confidential 1 If you cannot locate an individual in order to add Bill to ID(s) or enable.
From the Advanced Search page of the Cochrane Library, we have clicked on the Cochrane Reviews: By Topic hyperlink. This has displayed the Topics for Cochrane.
Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer Mayer EL et al. Proc SABCS 2010;Abstract P
Atrezzo Provider Portal Outpatient Case Creation July 2015 INTEGRATED CARE MANAGEMENT AND QUALITY IMPROVEMENT 1.
**INSERT YOUR TITLE HERE**
Interested In Online Giving Visit our parish website smcr.orgsmcr.org and click here.
S1400 Study Logistics Training Slides
Bernedine Lund/Sue Mann 5/6/09.  Baseline—All participants ◦ Serum ◦ Plasma (citrate & EDTA) ◦ Buffy coat ◦ Red blood cells ◦ Urine (BMD subsample—3.
Atrezzo Provider Portal Inpatient Case Creation July 2015 INTEGRATED CARE MANAGEMENT AND QUALITY IMPROVEMENT 1.
Human Research Protection Program 101 March 20, 2007 Cincinnati, OH.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.
May 2007 CTMS / Imaging Interoperability Scenarios March 2009.
Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.
ROAD MAP: Getting a Cancer Study Done at Jefferson Meghan Wakefield,RN,CCRP Senior Director of Clinical Trials Office Clinical Research Organization.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
FIRE1000S - Self-Paced FIREBIRD Training Training on the Federal Investigator Registry of Biomedical Informatics Research Data (FIREBIRD) for Clinical.
C3PR: An Introduction for Users A Tool Demonstration from caBIG™ Vijaya Chadaram Duke Cancer Center April 29, 2008.
The AHRQ Safety Program for Improving Antibiotic Use
Collaborative Practice Agreements
Markey Cancer Center Molecular Tumor Board.
MAINTAINING THE INVESTIGATOR’S SITE FILE
Using the Oregon POLST Registry
Value of Sequencing-Guided Treatment for Patients with
Coordination (benign lesions)
The AHRQ Safety Program for Improving Antibiotic Use
Accelerating Precision Medicine for Advanced Cancer Patients
EDRN’s Validation Study Information Management System
Biomarker Screening Pilot
S1400 Lung Master Protocol SWOG Spring meeting May 01, 2015
IMPAACT 2010 Screening Visits
Flu Vaccine Booking Guidance 20-Nov-18.
Using the Oregon POLST Registry
Alternate Assessment Updates
MAINTAINING THE INVESTIGATOR’S STUDY FILE
The College Application Process
Characterizing the Histologic Morphology of Liver Cancer: Creating a Formalin Fixed Paraffin Embedded Tissue Repository Tamar Taddei, MD.
Coverage and Reimbursement to Genetic Testing
SYNOPSIS OF THE PROTOCOL
UAB Tissue Biorepository
Presentation transcript:

The UWCCC/WON Molecular Tumor Board (MTB) & Registration Protocol Mark E. Burkard MD PhD WON fall meeting October 24, 2015

“I shall never be content until the beneficent influence of the University reaches every home of the state.” -Charles Van Hise 1904

Launched September 2015 UWCCC/WON Molecular Tumor Board Genetics experts oncologists, pathologists, pharmacologists, pharmacists, cancer researchers Submit pathology or genomics analysis Recommendations Clinical trial Off-label treatment Standard treatment (not targeted)

MTB Chairs & Collaborators UWCCC Mark Burkard, Dusty Deming & Josh Lang Research Jill Kolesar & Anne Traynor Laboratory Science Bill Rehrauer & Jennifer Laffin Pathology Kristina Matkowskyj & Darya Buehler WON Gundersen Lutheran/Lacrosse Dr. Ben M. Parsons St. Vincent/GB Oncology Dr. Ruth Warren

What to submit Clinical case information: Summary (age, diagnosis, stage, clinical status) Prior treatments for metastatic cancer Measurable disease (Y/N) Sample being tested Other clinically relevant information (clinical trial eligibility) Specific question Specimen and/or molecular data: Specimen for genomic testing Genomic test report

What you get Recommendation: – Clinical trials – Off label use of targeted drugs* – No recommendation *Recommendations will adhere to an dynamic guidance document that specifies when off-label therapies can be recommended.

MTB vs. Registration Protocol MTB: – Expert advice on precision medicine – Commitment to research and using the best clinical evidence Registration Protocol: – Research resource with genomic, clinical and outcome data – Available to WON members

The WON MTB Workflow

William Rehrauer Deaprtment of Pathology Request UW Pathology review/genomic sequencing UW Collaborative Genomics Core UWHC clinical labs

The WON MTB Workflow

The UWCCC Molecular Tumor Board

MTB Meetings When: 1 st and 3 rd Thursday of each month 4:30pm Where: UWCCC or Web-based Conference Who: Molecular tumor board chairs, trainees, WON collaborators, presenting physicians (optional) What: Present up to 4 cases, submitted 10 d prior Recommendation returned to treating physician Cost: $0 … but enroll patient in registry Cases are de-identified for presentation

The UWCCC MTB Registration Protocol

The MTB Registration Protocol To determine the frequency of acceptance of MTB clinical recommendations To evaluate effectiveness of precision targeted therapies

The MTB Registration Protocol Open to all pts > 18 yo with histologically confirmed solid or hematological malignancy who will have genetic testing Signed consent form All molecular tumor profiling laboratory reports allowed

Recruitment to the MTB Registration Protocol Presented and consented to subjects during regularly scheduled clinic appointments Subjects are registered into the UWCCC OnCore Database Baseline and follow up clinical, genetic and demographic information collected and stored in OnCore

Recruitment to the MTB & Registration Protocol Baseline Visit MTB Meeting (Days 14-28) Follow-up Visits while on molecularly-targeted therapy (if any) b Annually Informed Consent X Collect required data elements X X Obtain tumor tissue for genomic testing X XcXc Order genomic test a X XcXc Order MTB X Obtain DNA blood sample for Lang Lab, path slides for Kolesar Lab, and tissue for Deming Lab (if applicable) d X Query Wisconsin Cancer Registry X

Archived Tumor for the MTB Registration Protocol Formalin-fixed paraffin block (preferred) OR Five- 5 micron sections placed on positively charged slides  Slides should be labeled in a solvent-resistant manner with subject ID and slide numbers  Allow slides 1 and 3 to air dry for ~24 hrs prior to shipping  Slide 2 should be H&E stained and cover slipped prior to shipping  Slides 4 and 5 should be unstained

Blood Samples for the MTB Registration Protocol Prior to beginning targeted therapy: 2-10 mL Cellsave tubes 2-10mL EDTA tubes Formalin-fixed paraffin block (preferred) Samples will be processed for plasma and nucleated cells for analysis of cancer relevant targets and may be used to correlate with mutations observed in tumor tissue

Timelines MTB services are now available MTB Registration Protocol available early 2016

How to access MTB and testing

UW Collaborative Genomics Core Online Portal Access Portal Authorization Form Tests by Method Tests by Type Clinical Resources Genomic Research Resources

The OutReach Online Portal Hosted by the Wisconsin State Lab of Hygiene Used to:  Submit Requisition for Genomic Testing  Request MTB Consultation  View and print  UWCGC Test Reports  MTB Recommendations

The OutReach Online Portal The OutReach website address is OutReach can only be accessed by entering a valid user ID and password

The OutReach Online Portal Click on “Orders” (bottom right)

The OutReach Online Portal Click on “New Order” (lower left)

The OutReach Online Portal Submitting MD is selected by clicking “Set Submitter” (alphabetical list of MDs is displayed) Prior pts and new pts can be accessed here

The OutReach Online Portal Select “Order Type” (MTB) and select test to be ordered from the pull down MTB Prior pts and new pts can be accessed here Click “Place Order”

MTB Contact Information Marissa Schuh, Coordinator Dona Alberti, Administrator